$BMRN News

BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET

BioMarin and n-Lorem partner on early research for ReNU syndrome therapy

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome

BioMarin Pharmaceutical (NASDAQ:BMRN): A Value Stock with Strong Fundamentals

BioMarin Pharmaceutical Enters Global Exclusive License Agreement And Collaboration With n-Lorem Foundation To Develop A First-In-Disease, Antisense Oligonucleotide Medicine For People Living With ReNU Syndrome

BioMarin Pharmaceutical (NASDAQ:BMRN) Presents a High-Quality Breakout Setup with Strong Technical Ratings

BioMarin: Commercial Infrastructure Is The Hidden Growth Asset

2 Reasons to Avoid BMRN and 1 Stock to Buy Instead

Citigroup Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $76

FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo

BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $62

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Shows Strong Value Potential with a 7/10 Overall Rating

Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest

BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment

BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026

BioMarin Pharmaceutical Presented New Data From Phase 2 Three-Year Extension Study Of VOXZOGO In 13 Children With Hypochondroplasia That Demonstrated Sustained Improvements In Annualized Growth Velocity And Height Standard Deviation Score

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Decent Value Play with Strong Fundamentals